Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2021-06-18 Declaration of Voting R…
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Annual General Meeting of Shareholders of HLS THERAPEUTICS INC.' and dated June 18, 2021. It reports the voting results from the AGM, including election of directors, re-appointment of auditor, and approval of amendments to the stock option plan. The content focuses exclusively on the official results of shareholder votes at the AGM. There are no financial statements or detailed management discussions present. The document length is 2845 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2021-06-18 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release announcing the voting results from the Annual Meeting of Shareholders held by HLS Therapeutics Inc. It details the votes cast for individual director nominees and confirms shareholder approval of auditor appointment and stock option plan amendments. The document does not contain financial statements or detailed financial performance data, nor is it a full report. It is specifically focused on the results of shareholder voting at the Annual Meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it is an announcement rather than a full report, confirming the classification.
2021-06-18 English
News release - English.pdf
Investor Presentation Classification · 70% confidence The document is a press release announcing HLS Therapeutics' participation in a virtual non-deal roadshow event where the company will present to investors and hold a live Q&A session. It mentions an investor presentation but does not contain the presentation itself or any financial data. The document is short (2141 characters) and serves as an announcement of an event rather than a report or transcript. Therefore, it fits best under Investor Presentation (IP) as it focuses on a presentation for investors, but since the actual presentation is not included, it is more accurately an announcement related to an investor presentation event. However, since the document is primarily an announcement of participation in a virtual roadshow and not the presentation itself, the closest fitting category is Investor Presentation (IP) with moderate confidence.
2021-06-15 English
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing HLS Therapeutics' participation in a virtual non-deal roadshow event to discuss its latest investor presentation. It includes details about the event date, speakers, registration link, and company background. There is no actual financial data, report content, or detailed presentation included in the text. The document is an announcement about an upcoming investor presentation event rather than the presentation itself or a financial report. Given the nature of the content, the most appropriate classification is Investor Presentation (IP), as it relates to a presentation for investors focusing on financials, strategy, and market position, even though the document is an announcement of participation rather than the presentation itself. However, since the document is short and primarily an announcement of the event, it aligns best with the Investor Presentation category rather than a report publication announcement or regulatory filing.
2021-06-09 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of HLS Therapeutics Inc. scheduled for June 18, 2021. It includes voting instructions, appointment of proxyholders, and resolutions to be voted on, such as election of directors and reappointment of auditors. This type of document is used to solicit votes from shareholders prior to the AGM and is not the AGM presentation materials themselves, nor the voting results. It is a proxy solicitation document related to the AGM. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI). The document length is 5479 characters, which is consistent with a detailed proxy form. Therefore, the correct classification is PSI with high confidence.
2021-05-28 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual Meeting of Shareholders for HLS Therapeutics Inc., detailing the date, time, virtual format, agenda items including receiving audited financial statements, electing directors, reappointing auditors, and other shareholder meeting business. It is a formal announcement inviting shareholders to the meeting and providing instructions on voting and attendance. The document does not contain the actual financial statements or detailed reports but refers to the accompanying management information circular and proxy forms. The length is 4409 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices of the meeting itself.
2021-05-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.